No adverse impact on serum lipids of the irreversible aromatase inactivator aromasin (R) (Exemestane (E)) in first line treatment of metastatic breast cancer (MBC) : companion study to a European Organization of Research and Treatment of Cancer (Breast Group) Trial with Pharmacia and Upjohn
収録刊行物
-
- Proc Am Soc Clin Oncol
-
Proc Am Soc Clin Oncol 20 43a-, 2001
- Tweet
詳細情報
-
- CRID
- 1570009750057809536
-
- NII論文ID
- 10011164258
-
- データソース種別
-
- CiNii Articles